Joint European Congress on Biotechnology and IBS Congress rescheduled to 30 June – 3 July 2024
The Organising Committee of the Joint ECB and IBS Congress have taken the decision to reschedule the Congress in response to a thorough risk assessment in the wake of the pandemic.
The Joint ECB-IBS Congress will now take place from 30 June to 3 July 2024, still to be held at the MECC in Maastricht, The Netherlands.
We are disappointed to have to make this decision but the rising levels of infections currently and consequent threat of restrictions, plus the ongoing uncertainty about international travel mean that we cannot confidently plan for the Congress to go ahead successfully in 2022 as we had hoped. Instead, we believe the rescheduled Congress in 2024 will take place at a time of renewed confidence in face to face meetings, and will therefore fulfil its objectives to deliver the best scientific programme and networking opportunities to the global biotechnology community.
We thank you for your understanding. If you have any questions please do not hesitate to contact us at [email protected]
On behalf of everyone concerned with the organisation of the Congress, we wish you, your family, friends and colleagues good health during this challenging period.
For more information please visit: www.ecb2022.com